Clinical Trials
80 trialsNCT05824663 2026-05-04
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT05478486 2026-02-04
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
Godavari Biorefineries Limited
Phase 1 Completed
NCT04936178 2025-12-22
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Completed
NCT05155722 2025-12-08
Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Completed
NCT06001580 2025-11-21
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT02836600 2025-08-07
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT06007482 2025-06-23
A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT04278859 2025-06-19
Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Completed
NCT05075564 2025-05-14
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma, Ltd.
Phase 1 Completed
NCT05377528 2025-04-30
Study of AGEN1571 in Participants With Advanced Solid Tumors
Agenus Inc.
Phase 1 Completed
NCT05306444 2025-04-25
CLN-418 Study on Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT05463432 2025-03-20
A Study of HR19024 in Subjects With Advanced Solid Tumor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04608045 2025-03-03
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
Phase 1 Completed
NCT06172894 2025-02-12
PALINDROM
invIOs GmbH
Phase 1 Completed
NCT05178888 2025-02-11
Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT05169697 2025-01-06
A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT06228846 2025-01-03
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
Shanghai Yuyao Biotech Co., Ltd.
Phase 1 Completed
NCT05394818 2024-12-27
The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT05414136 2024-12-24
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006
Bio-Thera Solutions
Phase 1 Completed
NCT03457532 2024-11-01
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT05043298 2024-10-17
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03466268 2024-10-09
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT05065710 2024-09-03
A Study of ZL-1211 in Patients With Advanced Solid Tumor
Zai Lab (Hong Kong), Ltd.
Phase 1 Completed
NCT05101109 2024-07-31
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1 Completed
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT04675528 2024-07-25
FEEL
Daehwa Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04505839 2024-07-03
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
ST Pharm Co., Ltd.
Phase 1 Completed
NCT05594875 2024-06-25
A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
Phase 1 Completed
NCT04638491 2024-06-10
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Luye Pharma Group Ltd.
Phase 1 Completed
NCT05508100 2024-05-24
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
Immune-Onc Therapeutics
Phase 1 Completed
NCT04887194 2024-05-08
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
Mirati Therapeutics Inc.
Phase 1 Completed
NCT03874897 2024-04-30
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
Phase 1 Completed
NCT05001516 2024-04-17
Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Completed
NCT06372223 2024-04-17
A Food Effect Study of SPH5030 Tablets.
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT05051241 2024-03-01
A Study of GFH018 in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1 Completed
NCT06198556 2024-02-28
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04272944 2023-12-18
A Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1 Completed
NCT04162327 2023-10-24
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04357756 2023-09-13
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT04912466 2023-09-06
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03499444 2023-06-09
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT04989829 2023-06-08
Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT04088604 2023-04-26
Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1 Completed
NCT04135261 2023-04-18
A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors
Harbour BioMed US, Inc.
Phase 1 Completed
NCT04060511 2023-03-09
A Study of HS-10342 in Patients With Advanced Solid Tumor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT03758001 2023-02-22
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04324814 2023-02-21
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
Atridia Pty Ltd.
Phase 1 Completed
NCT04049903 2022-12-22
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
Molecular Partners AG
Phase 1 Completed
NCT04097769 2022-12-12
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Waterstone Hanxbio Pty Ltd
Phase 1 Completed